Results 121 to 130 of about 15,585 (162)

Subacute Stent Thrombosis Revealing High On-Treatment Platelet Reactivity to Clopidogrel: A Case Report. [PDF]

Cureus
Nabhan E, Andriamihary O, Naoum Nehme E, Vana AP, Poulos N.   +4 more
europepmc   +1 more source

Ticagrelor-induced sinus pause: an adenosine-driven side effect. [PDF]

BMJ Case Rep
Fanning JK, Barnes AAB, Betley F, Sondhi S.   +3 more
europepmc   +1 more source

Overcoming Clopidogrel Resistance in Carotid Artery Stenting: Experience with Ticagrelor and Ticlopidine. [PDF]

Clin Pract
Vigláš P, Raupach J, Hejčl A, Černík D, Bradáčová P, Matras P, Cihlář F.   +6 more
europepmc   +1 more source

Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study.

Cardiorenal Med
Sun WC, Lee HF, Lin C, Huang SC, Chen JJ, Ho WY, Yen CL, Hsiao CC.   +7 more
europepmc   +1 more source

Implementing a CYP2C19-guided approach for prescribing dual antiplatelet therapy in acute coronary syndrome for patients undergoing percutaneous coronary intervention: a cost-effectiveness analysis

Mahboub-Ahari A, Hilton J, Rodrigues M, McDermott J, Body R, Newman WG, Payne K.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ticagrelor

2022
Ticagrelor is one of the most recent antiplatelet agents used to inhibit platelet aggregation via blocking the ADP receptors of the subtype P2Y12. It belongs to the non-thienopyridine class. The drug was first discovered by Astra Zeneca and approved for use in 2011 by the FDA.
Mohamed Fawzy, Kabil, Ahmed S, Abo Dena, Ibrahim M, El-Sherbiny   +2 more
openaire   +2 more sources

Ticagrelor

Reactions Weekly, 2018
  +11 more sources